JP2015506926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506926A5 JP2015506926A5 JP2014548277A JP2014548277A JP2015506926A5 JP 2015506926 A5 JP2015506926 A5 JP 2015506926A5 JP 2014548277 A JP2014548277 A JP 2014548277A JP 2014548277 A JP2014548277 A JP 2014548277A JP 2015506926 A5 JP2015506926 A5 JP 2015506926A5
- Authority
- JP
- Japan
- Prior art keywords
- process according
- salt
- concentration
- column
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579609P | 2011-12-22 | 2011-12-22 | |
| US61/579,609 | 2011-12-22 | ||
| US201261644831P | 2012-05-09 | 2012-05-09 | |
| US61/644,831 | 2012-05-09 | ||
| PCT/IB2012/057227 WO2013093720A2 (en) | 2011-12-22 | 2012-12-12 | Anti-diabetic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506926A JP2015506926A (ja) | 2015-03-05 |
| JP2015506926A5 true JP2015506926A5 (enExample) | 2016-02-04 |
| JP6165168B2 JP6165168B2 (ja) | 2017-07-19 |
Family
ID=47561699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548277A Expired - Fee Related JP6165168B2 (ja) | 2011-12-22 | 2012-12-12 | 抗糖尿病化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9163227B2 (enExample) |
| EP (1) | EP2793928B1 (enExample) |
| JP (1) | JP6165168B2 (enExample) |
| KR (1) | KR101640697B1 (enExample) |
| CN (1) | CN104066438B (enExample) |
| AU (1) | AU2012356219B2 (enExample) |
| BR (1) | BR112014014898A2 (enExample) |
| CA (1) | CA2859969A1 (enExample) |
| DK (1) | DK2793928T3 (enExample) |
| ES (1) | ES2623786T3 (enExample) |
| IL (1) | IL233206A (enExample) |
| MX (1) | MX2014007626A (enExample) |
| SG (1) | SG11201402640SA (enExample) |
| TW (1) | TWI560202B (enExample) |
| WO (1) | WO2013093720A2 (enExample) |
| ZA (1) | ZA201403755B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| IL282614B2 (en) * | 2015-02-06 | 2024-02-01 | Cell Idx Inc | Antigen-conjugated immune reagents |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| KR102403089B1 (ko) * | 2017-07-05 | 2022-06-02 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도 |
| US11945839B2 (en) | 2017-12-22 | 2024-04-02 | Hoffmann-La Roche Inc. | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| KR20210027426A (ko) * | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
| CN116917311A (zh) * | 2020-12-17 | 2023-10-20 | I2O治疗公司 | 长效胰高血糖素样多肽-1(glp-1)受体激动剂和其使用方法 |
| CN112986575B (zh) * | 2020-12-29 | 2023-03-17 | 上海药明康德新药开发有限公司 | 一种串联式验证dna编码苗头化合物修饰抗体的方法 |
| TW202423476A (zh) * | 2021-03-23 | 2024-06-16 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| JP2024516834A (ja) * | 2021-04-30 | 2024-04-17 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | Ｏｘｍ３保存剤、ｏｘｍ３製剤および調製方法 |
| EP4400094A4 (en) * | 2021-09-07 | 2025-08-27 | D&D Pharmatech Inc | PHARMACEUTICAL COMPOSITION COMPRISING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND AN EXCIPIENT |
| US12233115B2 (en) | 2022-09-30 | 2025-02-25 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2024238912A1 (en) * | 2023-05-17 | 2024-11-21 | OncoC4, Inc. | Ph-sensitive anti-ctla-4 antibodies and uses thereof |
| CN116804630B (zh) * | 2023-08-03 | 2024-03-05 | 中拓生物有限公司 | 一种血清同型半胱氨酸测定试剂盒 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU1190101A (en) | 1999-09-27 | 2001-04-30 | Regents Of The University Of California, The | Engineering antibodies that bind irreversibly |
| US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| PT1232264E (pt) | 1999-11-18 | 2009-11-26 | Novartis Vaccines & Diagnostic | Gene fgf-21 humano e produtos da expressão do gene |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| WO2003059270A2 (en) | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
| EP2270163A1 (en) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
| WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
| WO2005091944A2 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| PL1751184T3 (pl) | 2004-05-13 | 2010-02-26 | Lilly Co Eli | Białka fuzyjne FGF-21 |
| BRPI0514790A (pt) | 2004-09-02 | 2008-06-24 | Lilly Co Eli | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano |
| EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
| CN101287485A (zh) * | 2005-03-03 | 2008-10-15 | 爱尔兰考夫克斯科技有限公司 | 抗血管生成化合物 |
| JP5167473B2 (ja) * | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| US20110034373A1 (en) * | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
-
2012
- 2012-12-12 JP JP2014548277A patent/JP6165168B2/ja not_active Expired - Fee Related
- 2012-12-12 US US13/712,873 patent/US9163227B2/en not_active Expired - Fee Related
- 2012-12-12 EP EP12816137.9A patent/EP2793928B1/en not_active Not-in-force
- 2012-12-12 KR KR1020147020397A patent/KR101640697B1/ko not_active Expired - Fee Related
- 2012-12-12 WO PCT/IB2012/057227 patent/WO2013093720A2/en not_active Ceased
- 2012-12-12 TW TW101147080A patent/TWI560202B/zh not_active IP Right Cessation
- 2012-12-12 SG SG11201402640SA patent/SG11201402640SA/en unknown
- 2012-12-12 BR BR112014014898-8A patent/BR112014014898A2/pt not_active IP Right Cessation
- 2012-12-12 ES ES12816137.9T patent/ES2623786T3/es active Active
- 2012-12-12 CA CA2859969A patent/CA2859969A1/en not_active Abandoned
- 2012-12-12 AU AU2012356219A patent/AU2012356219B2/en not_active Ceased
- 2012-12-12 DK DK12816137.9T patent/DK2793928T3/en active
- 2012-12-12 CN CN201280063933.4A patent/CN104066438B/zh not_active Expired - Fee Related
- 2012-12-12 MX MX2014007626A patent/MX2014007626A/es unknown
-
2014
- 2014-05-22 ZA ZA2014/03755A patent/ZA201403755B/en unknown
- 2014-06-17 IL IL233206A patent/IL233206A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518883A5 (enExample) | ||
| Dall’Acqua et al. | Antibody humanization by framework shuffling | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| RU2019102008A (ru) | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа | |
| JP2016196468A5 (enExample) | ||
| FI3309176T3 (fi) | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö | |
| JP2019500862A5 (enExample) | ||
| JP2010227116A5 (enExample) | ||
| JP2015525211A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| EP1819830A4 (en) | METHODS FOR ANTIBODY ENGINEERING | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| JP2017536114A5 (enExample) | ||
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| JP2017517745A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| TW201249999A (en) | An integrated approach to the isolation and purification of antibodies | |
| JP2008520186A5 (enExample) | ||
| JP2015501836A (ja) | 抗体の精製方法 | |
| JP2015537190A5 (enExample) | ||
| JP2017536846A5 (enExample) | ||
| JP2017532005A5 (enExample) | ||
| JP2016519052A5 (enExample) | ||
| JP6009431B2 (ja) | アフィニティー精製の方法 |